Evidenzbasierte Therapie der Demodikose des Hundes

R. S. Mueller

doi:10.1055/s-0038-1623606

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Table of Contents

Tierarztl Prax Ausg K Kleintiere Heimtiere 2011; 39(06): 419-424
DOI: 10.1055/s-0038-1623606

Übersichtsartikel

Schattauer GmbH

Evidenzbasierte Therapie der Demodikose des Hundes

Evidence-based treatment of canine demodicosis

R. S. Mueller

¹Medizinische Kleintierklinik, Zentrum für klinische Tiermedizin, Ludwig-Maximilians-Universität München

› Author Affiliations

Abstract

Zusammenfassung

Dieser Artikel gibt nach einer kurzen Übersicht über Pathogenese, klinische Symptomatik und Diagnose der Demodikose des Hundes eine Zusammenfassung der Behandlungsmöglichkeiten basierend auf publizierten Wirksamkeitsstudien. Die Krankheit beruht auf einer exzessiven Proliferation von Demodex-Milben in den Haarfollikeln, die durch genetische Faktoren, immunsuppressive Krankheiten oder Therapien hervorgerufen sein kann. Das klinische Bild manifestiert sich in Form von Alopezie, Papeln, Pusteln und Krusten. Die Diagnose erfolgt durch den Nachweis mehrerer Milben in tiefen Hautgeschabseln oder Trichogrammen. Veröffentlichten Studien zufolge sind wöchentliche Spülungen mit Amitraz in einer Konzentration von 0,05% und (bei geringbis mittelgradig ausgeprägter Symptomatik) eine wöchentliche Spot-onBehandlung mit Moxidectin zugelassene und in vielen Fällen wirksame Therapien. Bei schweren, behandlungsresistenten Fällen können als orale Medikation makrozyklische Laktone wie Milbemycinoxim (1–2 mg/kg KM täglich), Ivermectin oder Moxidectin (0,3 mg/kg KM täglich nach täglicher gradueller Dosiserhöhung ) Anwendung finden. Auch eine wöchentliche Applikation von Doramectin in einer Dosis von 0,6 mg/kg KM subkutan oder oral erwies sich in Studien als erfolgreich. Die Behandlung der in der Regel vorhandenen bakteriellen Sekundärinfektion sollte mit antibakteriellen Shampoos und gegebenenfalls oral verabreichten Antibiotika erfolgen.

Summary

This article briefly reviews pathogenesis, clinics and diagnosis of canine demodicosis and summarizes treatment options for this disease based on published evidence. The disease is caused by excessive proliferation of Demodex mites in the hair follicles that may be due to genetic factors or immunosuppressive diseases or treatments. The disease is characterized by alopecia, papules, pustules and crusts. Diagnosis is confirmed by detection of several mites in deep skin scrapings or trichograms. Based on published studies, licensed successful treatments for many patients are weekly amitraz rinses in a concentration of 0.05% and (in dogs with mild to moderate clinical signs) weekly spot-ons containing moxidectin. In severe, treatment-resistant cases, daily oral macrocyclic lactones such as milbemycin oxim (1–2 mg/kg), ivermectin or moxidectin (0.3 mg/kg after daily gradual dose increases from 0.05 mg/kg) may be used. Doramectin orally or subcutaneously at 0.6 mg/kg has also been reported as successful therapy. Secondary bacterial skin infections are common and should be treated with antimicrobial shampoos and possibly oral antibiotics.

Schlüsselwörter

Hund - Milben - Demodex - Amitraz - Ivermectin - Moxidectin - Milbemycin - Doramectin - Behandlung

Key words

Canine - mites - Demodex - amitraz - ivermectin - moxidectin - milbemycin - doramectin - therapy

Full Text

References

Literatur
1 Beco L, Fontaine F, Bergvall K, Favrot C. Comparison of skin scrapes and hair plucks for detecting Demodex mites in canine demodicosis, a multicentre, prospective study. In: Abstracts of the Annual Conference of the European Society of Veterinary Dermatology/European College of Veterinary Dermatology, Mainz. Vet Dermatol 2007; 18: 381.
2 Bissonnette S, Paradis M, Daneau I, Silversides DW. The ABCB1–1Delta mutation is not responsible for subchronic neurotoxicity seen in dogs of noncollie breeds following macrocyclic lactone treatment for generalized demodicosis. Vet Dermatol 2009; 20: 60-66.
3 Bourdeau P. Variation in size in Demodex canis: from the longest to the shortest forms. In: Proceedings of the 24th Annual Congress of the ESVD/ECVD 2010, Florence, 2010; 213.
4 Bruzinska-Schmidhalter R, Nett-Mettler CS. Spontaneous remission in canine generalized demodicosis – predisposing factors. In: Abstracts of the North American Veterinary Dermatology Forum, Galveston. Vet Dermatol 2011; 22: 301.
5 Chesney CJ. Short form of Demodex species mite in the dog: occurrence and measurements. J Small Anim Pract 1999; 40: 58-61.
6 Desch CE, Hillier A. Demodex injai: a new species of hair follicle mite (Acari: Demodecidae) from the domestic dog (Canidae). J Med Entomol 2003; 40: 146-149.
7 Duclos DD, Jeffers JG, Shanley KJ. Prognosis for treatment of adult-onset demodicosis in dogs: 34 cases (1979–1990). J Am Vet Med Assoc 1994; 204: 616-619.
8 Fourie LJ, Kok DJ, du Plessis A, Rugg D. Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of demodectic mange in dogs. Vet Parasitol 2007; 150: 268-274.
9 Geyer J, Klintzsch S, Meerkamp K, Wohlke A, Distl O, Moritz A, Petzinger E. Detection of the nt230(del4) MDR1 mutation in White Swiss Shepherd dogs: case reports of doramectin toxicosis, breed predisposition, and microsatellite analysis. J Vet Pharmacol Ther 2007; 30: 482-485.
10 Greve JH, Gaafar SM. Natural transmission of Demodex canis in dogs. J Am Vet Med Assoc 1966; 148: 1043-1045.
11 Heine J, Krieger K, Dumont P, Hellmann K. Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study. Parasitol Res 2005; 97 (Suppl. 01) S89-96.
12 Hugnet C, Bruchon-Hugnet C, Royer H, Bourdoiseau G. Efficacy of 1.25% amitraz solution in the treatment of generalized demodicosis (eight cases) and sarcoptic mange (five cases) in dogs. Vet Dermatol 2001; 12: 89-92.
13 Johnstone IP. Doramectin as a treatment for canine and feline demodicosis. Austr Vet Practit 2002; 32: 98-103.
14 Kwochka KW, Kunkle GA, Foil CS. The efficacy of amitraz for generalized demodicosis in dogs: A study of two concentrations and frequencies of application. Comp Cont Educ 1985; 07: 8-17.
15 Lavy E, Aroch I, Bark H, Markovics A, Aizenberg I, Mazaki-Tovi M, Hagag A, Harrus S. Evaluation of doramectin for the treatment of experimental canine spirocercosis. Vet Parasitol 2002; 109: 65-73.
16 Lemarie S, Hosgood G, Foil CS. A retrospective study of juvenileand adultonset generalized demodicosis in dogs (1986–1991). Vet Dermatol 1996; 07: 3-10.
17 Mayer UK, Glos K, Schmid M, Power HT, Bettenay SV, Mueller RS. Adverse effects of ketoconazole in dogs – a retrospective study.Vet Dermatol. 2008; 19: 199-208.
18 Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11: 727-733.
19 Mueller RS, Bettenay SV. A proposed new therapeutic protocol for the treatment of canine mange with ivermectin. J Am Anim Hosp Assoc 1999; 35: 77-80.
20 Mueller RS. Treatment protocols for demodicosis: an evidence-based review. Vet Dermatol 2004; 15: 75-89.
21 Mueller RS, Meyer D, Bensignor E, Sauter-Louis C. Treatment of canine generalized demodicosis with a ‘spot-on’ formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare).Vet Dermatol. 2009; 20: 441-446.
22 Mueller RS, Bettenay SV. Skin scrapings and skin biopsies. In: Textbook of Veterinary Internal Medicine. 7th ed.. Ettinger SJ, Feldman EC. eds. Philadelphia: Saunders; 2010: 368-371.
23 Mueller RS, Bensignor E, Ferrer L, Holm BR, Lemarie S, Paradis M, Shipstone MA. Treatment of Demodicosis in Dogs: 2011 Clinical Practice Guidelines. Vet Dermatol. (in press).
24 Murayama N, Shibata K, Nagata M. Efficacy of weekly oral doramectin treatment in canine demodicosis. Vet Rec 2010; 167: 63-64.
25 Oberkirchner U, Linder K, Olivry T. Promeris-associated pemphigus foliaceus-like drug reactions in dogs: 22 cases. In: Abstracts of the North American Veterinary Dermatology Forum, Portland. Vet Dermatol 2010; 23: 319.
26 Paterson TE, Halliwell RE, Fields PJ, Louw ML, Louw JP, Ball GS, Pinckney RD, McKibben JS. Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate (Bayer Animal Health) with ivermectin. Vet Dermatol 2009; 20: 447-455.
27 Plant JD, Lund EM, Yang M. A case-control study of the risk factors for canine juvenile-onset generalized demodicosis in the USA. Vet Dermatol 2011; 22: 95-99.
28 Rosenkrantz W. Efficacy of metaflumizone plus amitraz for the treatment of juvenile and adult onset demodicosis in dogs: pilot study of 24 dogs. In: Abstracts of the North American Veterinary Dermatology Forum, Savannah. Vet Dermatol 2009; 20: 227.
29 Schnabl B, Bettenay S, Glos N, Linek M, Loewenstein C, Mueller RS. Oral selamectin in the treatment of canine generalised demodicosis. Vet Rec 2010; 166: 710-714.
30 Scott DW, Walton DK. Experiences with the use of amitraz and ivermectin for the treatment of generalized demodicosis in dogs. J Am Anim Hosp Assoc 1985; 21: 535-541.
31 Scwott DW, Miller Jr WH, Giriffin CE. Canine Demodicosis. In: Small Animal Dermatology. 6th ed.. Philadelphia: Saunders; 2001: 457-474.
32 Yas-Natan E, Shamir M, Kleinbart S, Aroch I. Doramectin toxicity in a collie. Vet Rec 2003; 153: 718-720.